About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Enliven Therapeutics, Inc. (ELVN): Insider Trades and Fund Holdings
In the past 12 months, Enliven Therapeutics, Inc. insiders reported no open-market purchases and 15 sales worth $65.0M; 12 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 19, 2026Insider saleCFO Benjamin Hohl sold $231,546 under a 10b5-1 plan (5 days after: executive or director change)
- Oct 19, 2026Insider saleCHIEF MEDICAL OFFICER Helen Louise Collins sold $192,342 under a 10b5-1 plan (5 days after: executive or director change)
- Oct 19, 2026Planned saleCollins Helen Louise (director) filed notice to sell about $559,800 around Oct 19, 2026
- Oct 14, 2026NewsCompany reported: Executive or director change
- Oct 1, 2026Insider saleDirector J. Scott Garland sold $606,719
- Oct 1, 2026Planned saleJEFFREY GARLAND (director) filed notice to sell about $606,719 around Oct 1, 2026
- Sep 17, 2026Insider saleCFO Benjamin Hohl sold $303,002 under a 10b5-1 plan
- Sep 17, 2026Insider saleCHIEF MEDICAL OFFICER Helen Louise Collins sold $251,754 under a 10b5-1 plan
- Sep 17, 2026Planned saleHohl Benjamin (officer) filed notice to sell about $591,208 around Sep 17, 2026
- Sep 4, 2026Planned saleHeyman Richard A. (resigned from bod) filed notice to sell about $2.3 million around Sep 4, 2026
- Aug 17, 2026Insider saleCFO Benjamin Hohl sold $352,551 under a 10b5-1 plan
- Aug 17, 2026Insider saleCHIEF MEDICAL OFFICER Helen Louise Collins sold $292,931 under a 10b5-1 plan
- Aug 4, 2026Insider saleDirector Mika K. Derynck sold $9.6 million under a 10b5-1 plan
- Jul 17, 2026Insider saleCFO Benjamin Hohl sold $316,780 under a 10b5-1 plan
- Jul 17, 2026Insider saleCHIEF MEDICAL OFFICER Helen Louise Collins sold $263,374 under a 10b5-1 plan
- Jul 6, 2026Insider saleDirector Lori Anne Kunkel sold $504,903 under a 10b5-1 plan
- Jun 22, 2026Insider sale10% owner Orbimed Advisors LLC sold $39 million
- Jun 17, 2026Insider saleCFO Benjamin Hohl sold $263,577 under a 10b5-1 plan
- Jun 17, 2026Insider saleCHIEF MEDICAL OFFICER Helen Louise Collins sold $219,017 under a 10b5-1 plan
- Jun 15, 2026Insider sale10% owner Orbimed Advisors LLC sold $12.7 million
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 21, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 21 | Benjamin HohlCFO | ▼ SELL10b5-1 | $232K |
| Oct 21 | Helen Louise CollinsCHIEF MEDICAL OFFICER | ▼ SELL10b5-1 | $192K |
| Oct 5 | J. Scott GarlandDirector | ▼ SELL | $607K |
| Sep 21 | Benjamin HohlCFO | ▼ SELL10b5-1 | $303K |
| Sep 21 | Helen Louise CollinsCHIEF MEDICAL OFFICER | ▼ SELL10b5-1 | $252K |
| Aug 19 | Benjamin HohlCFO | ▼ SELL10b5-1 | $353K |
| Aug 19 | Helen Louise CollinsCHIEF MEDICAL OFFICER | ▼ SELL10b5-1 | $293K |
| Aug 6 | Mika K. DerynckDirector | ▼ SELL10b5-1 | $9.56M |
| Jul 21 | Benjamin HohlCFO | ▼ SELL10b5-1 | $317K |
| Jul 21 | Helen Louise CollinsCHIEF MEDICAL OFFICER | ▼ SELL10b5-1 | $263K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Benjamin Hohl | CFO | 0 | $0 | 5 | $1.47M |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $1.22M |
| J. Scott Garland | Director | 0 | $0 | 1 | $607K |
| Mika K. Derynck | Director | 0 | $0 | 1 | $9.56M |
| Lori Anne Kunkel | Director | 0 | $0 | 1 | $505K |
| Orbimed Advisors LLC | 10% owner | 0 | $0 | 2 | $51.7M |
A All 15 insider trades reported on time. How it is graded
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →